Latest Market Expectations News

EVT Limited has responded to ASX inquiries confirming its FY25 earnings were broadly in line with market forecasts, despite a notable post-results share price decline.

Codan Limited has clarified that its FY25 financial results aligned closely with market forecasts despite a notable share price jump following its earnings release. The company detailed its compliance with ASX disclosure rules and attributed the price movement to broader macroeconomic factors.

Carbonxt Group Limited reported a 7.1% revenue increase to $16.2 million in FY25 alongside a 16.7% reduction in net loss, while progressing its Kentucky liquid-phase activated carbon facility and navigating ongoing liquidity challenges.

DigiCo Infrastructure REIT confirms its FY25 EBITDA slightly exceeded IPO guidance and aligned with analyst forecasts, attributing recent share price declines to the absence of FY26 earnings guidance.

SomnoMed has delivered a standout FY25 with revenue and EBITDA exceeding market expectations, driven by strong regional growth and operational improvements. The company is now expanding capacity and advancing its innovative Rest Assure device.

Thorney Opportunities Ltd posted a sharp 76% decline in profit after tax for FY2025 yet declared a higher fully franked final dividend and reported growth in net tangible assets per share.

Shriro Holdings reported a 5.5% rise in EBITDA for FY25 despite a 13.6% revenue dip, driven by strategic shifts including a new US distributor and innovative BBQ product launches.

James Hardie Industries confirms its Q1 FY26 earnings met market expectations despite a challenging North American housing market, while revising its FY26 guidance following the AZEK acquisition.

AGL Energy has clarified that its FY25 underlying earnings aligned with market forecasts and published guidance, dismissing any material surprises in its financial results. The company also addressed statutory profit volatility and confirmed compliance with ASX disclosure rules.

Healius reported a 5.7% rise in FY25 revenue with underlying EBIT meeting consensus, buoyed by strong pathology growth and a significant profit from the Lumus Imaging sale. Despite challenges at Agilex Biolabs and a major goodwill impairment, the company targets improved margins by 2027.

Medical Developments International reports a strong FY25 with significant margin gains and strategic progress, setting the stage for accelerated Penthrox expansion in FY26.

Bega Cheese Limited has announced a fully franked ordinary dividend of AUD 0.06 per share for the half-year ending June 2025, alongside a Dividend Reinvestment Plan offering shareholders a choice to reinvest without discount.